AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18581975 — intervention group
Group type: COMPARATOR
Intervention: Comparison of current findings with previous study
Number of subjects: 156
Study 18581975 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin prick tests (SPTs) in town dwellers
Number of subjects: 156
Study 18581975 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin prick tests (SPTs) in rural areas
Number of subjects: 156
Study 15621380 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 15621380 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (1800 mg/day)
Number of subjects: 110
Study 15621380 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib (50 mg/day)
Number of subjects: 110
Study 15621380 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin-Rofecoxib combination (1800/50 mg/day)
Number of subjects: 110
Study 12162469 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (low dose: 0.625 or 1.25 mg, middle dose: 2.5 or 5 mg, high dose: 20 or 40 mg)
Number of subjects: 110
Study 12162469 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (middle and high dose)
Number of subjects: 110
Study 12162469 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 10078669 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (15 microg/kg)
Number of subjects: 93
Study 10078669 — intervention group
Group type: COMPARATOR
Intervention: Glycopyrrolate (10 microg/kg)
Number of subjects: 93
Study 7750159 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 mg DHC
Number of subjects: 18
Study 7750159 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg tramadol
Number of subjects: 18
Study 7750159 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 2406406 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued breast-feeding during rotaviral gastroenteritis
Number of subjects: 0
Study 2406406 — intervention group
Group type: COMPARATOR
Intervention: Lactose-free soya feeds
Number of subjects: 0
Study 2406406 — intervention group
Group type: COMPARATOR
Intervention: Cow's milk-formula feeds
Number of subjects: 0
Study 6989549 — intervention group
Group type: EXPERIMENTAL
Intervention: Low abrasivity paste containing 0.8% sodium monofluorophosphate
Number of subjects: 1106
Study 6989549 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional abrasivity paste containing 0.8% sodium monofluorophosphate
Number of subjects: 1106
Study 6989549 — intervention group
Group type: COMPARATOR
Intervention: Low abrasivity non-fluoride paste
Number of subjects: 1106
Study 30333407 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic Band Ligation (EBL)
Number of subjects: 135
Study 30333407 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic Clipping (EC)
Number of subjects: 135
Study 30333407 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factor analysis
Number of subjects: 135
Study 29998139 — intervention group
Group type: EXPERIMENTAL
Intervention: Group care
Number of subjects: 60
Study 29998139 — intervention group
Group type: COMPARATOR
Intervention: Individual care
Number of subjects: 60
Study 26631343 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle fasciotomy
Number of subjects: 93
Study 26631343 — intervention group
Group type: COMPARATOR
Intervention: Collagenase injection
Number of subjects: 93
Study 24665646 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-core crown restoration
Number of subjects: 30
Study 21979272 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month physical therapist-prescribed balance and strength home exercise program
Number of subjects: 165
Study 21979272 — intervention group
Group type: COMPARATOR
Intervention: Usual activities (control group)
Number of subjects: 165
Study 19158209 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g cinnamon
Number of subjects: 15
Study 19158209 — intervention group
Group type: COMPARATOR
Intervention: 1 g cinnamon
Number of subjects: 15
Study 17541317 — intervention group
Group type: EXPERIMENTAL
Intervention: RISKO Heart Hazard Appraisal to quantify CAD risk factor burden
Number of subjects: 152
Study 15562929 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Number of subjects: 5
Study 11078906 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced training (1 session/wk)
Number of subjects: 21
Study 11078906 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced training (2 or 1 session(s)/wk)
Number of subjects: 21
Study 11078906 — intervention group
Group type: EXPERIMENTAL
Intervention: Detraining (0 session/wk)
Number of subjects: 21
Study 11078906 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 21
Study 9338047 — intervention group
Group type: EXPERIMENTAL
Intervention: Deflazacort (DFZ)
Number of subjects: 72
Study 9338047 — intervention group
Group type: COMPARATOR
Intervention: Prednisone (PDN)
Number of subjects: 72
Study 8403174 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2.5 mg.kg‐1
Number of subjects: 72
Study 8403174 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone 5 mg.kg‐1
Number of subjects: 72
Study 2943994 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol (beta-2 adrenergic agent)
Number of subjects: 11
Study 2943994 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (anticholinergic agent)
Number of subjects: 11
Study 2943994 — intervention group
Group type: COMPARATOR
Intervention: Albuterol followed by Ipratropium bromide
Number of subjects: 11
Study 2943994 — intervention group
Group type: COMPARATOR
Intervention: Ipratropium bromide followed by Albuterol
Number of subjects: 11
Study 2943994 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 31944869 — intervention group
Group type: EXPERIMENTAL
Intervention: VAULT treatment (3 target words/90 doses per word per session)
Number of subjects: 24
Study 31944869 — intervention group
Group type: EXPERIMENTAL
Intervention: VAULT treatment (6 target words/45 doses per word per session)
Number of subjects: 24
Study 31944869 — intervention group
Group type: COMPARATOR
Intervention: No-treatment condition
Number of subjects: 24
Study 30306222 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous moderate-intensity exercise (CMIE)
Number of subjects: 27
Study 30306222 — intervention group
Group type: COMPARATOR
Intervention: Low-volume high-intensity interval exercise (LV-HIIE)
Number of subjects: 27
Study 28164208 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic hemodialysis patients
Number of subjects: 714
Study 28164208 — intervention group
Group type: EXPERIMENTAL
Intervention: Older patients (≥75 years)
Number of subjects: 714
Study 28164208 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin levels
Number of subjects: 714
Study 25974146 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) program, 8 sessions, guided internet-based CBT for students identified as actively suicidal or at higher risk.
Number of subjects: 3244
Study 25974146 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT program participants (163 out of 503 offered, 32%)
Number of subjects: 3244
Study 25974146 — intervention group
Group type: COMPARATOR
Intervention: Control group (students who did not participate in CBT)
Number of subjects: 3244
Study 25974146 — intervention group
Group type: COMPARATOR
Intervention: Overall population screened
Number of subjects: 3244
Study 24019074 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 121
Study 24019074 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 121
Study 21374657 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF)
Number of subjects: 641
Study 21374657 — intervention group
Group type: COMPARATOR
Intervention: Adefovir dipivoxil (ADV)
Number of subjects: 641
Study 18304211 — intervention group
Group type: EXPERIMENTAL
Intervention: α1-Adrenoceptor antagonists (blockers)
Number of subjects: 0
Study 17175307 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL) + CsA + prednisolone
Number of subjects: 41
Study 17175307 — intervention group
Group type: COMPARATOR
Intervention: MMF + CsA + prednisolone
Number of subjects: 41
Study 17175307 — intervention group
Group type: COMPARATOR
Intervention: CsA + AZA + prednisolone
Number of subjects: 41
Study 14668957 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant external beam radiotherapy (RTx)
Number of subjects: 311
Study 14668957 — intervention group
Group type: COMPARATOR
Intervention: No external beam radiotherapy (no RTx)
Number of subjects: 311
Study 11081889 — intervention group
Group type: EXPERIMENTAL
Intervention: IRWSE + cold blood (CB)
Number of subjects: 67
Study 11081889 — intervention group
Group type: COMPARATOR
Intervention: cold blood (CB)
Number of subjects: 67
Study 9258475 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) and oral anticoagulant (group A)
Number of subjects: 175
Study 9258475 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA) and ticlopidine (group B)
Number of subjects: 175
Study 8337194 — intervention group
Group type: EXPERIMENTAL
Intervention: Group education program based on social learning theory and the 'Arthritis Self‐Management Course'
Number of subjects: 0
Study 8337194 — intervention group
Group type: EXPERIMENTAL
Intervention: Group education program
Number of subjects: 0
Study 2427845 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (1, 1, 2, and 4 mg)
Number of subjects: 24
Study 2427845 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol (1, 1, 2, and 4 mg)
Number of subjects: 24
Study 2427845 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol and Celiprolol during exercise
Number of subjects: 24
Study 2427845 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 24
Study 2427845 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol
Number of subjects: 24
Study 31791288 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium zirconium cyclosilicate (SZC) 10 g three times daily
Number of subjects: 170
Study 29897951 — intervention group
Group type: EXPERIMENTAL
Intervention: Flashlight guidance
Number of subjects: 121
Study 29897951 — intervention group
Group type: COMPARATOR
Intervention: Control (no flashlight guidance)
Number of subjects: 121
Study 28286995 — intervention group
Group type: EXPERIMENTAL
Intervention: Dates consumption
Number of subjects: 154
Study 28286995 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dates consumption)
Number of subjects: 154
Study 25787197 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI with a sirolimus‐eluting stent
Number of subjects: 600
Study 25787197 — intervention group
Group type: COMPARATOR
Intervention: CABG
Number of subjects: 600
Study 23228222 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline (NOR) added to multi-component smoking cessation intervention (CBT and NRT)
Number of subjects: 425
Study 23228222 — intervention group
Group type: COMPARATOR
Intervention: Placebo added to multi-component smoking cessation intervention (CBT and NRT)
Number of subjects: 425
Study 21908175 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 62
Study 21908175 — intervention group
Group type: EXPERIMENTAL
Intervention: Befriending
Number of subjects: 62
Study 18163419 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific strength training for the affected muscle
Number of subjects: 48
Study 18163419 — intervention group
Group type: EXPERIMENTAL
Intervention: General fitness training (leg bicycling with relaxed shoulders)
Number of subjects: 48
Study 18163419 — intervention group
Group type: COMPARATOR
Intervention: Reference intervention without physical activity
Number of subjects: 48
Study 17050869 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 75 mg/m2 plus pemetrexed 500 mg/m2
Number of subjects: 78
Study 17050869 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin AUC 5 plus pemetrexed 500 mg/m2
Number of subjects: 78
Study 12716335 — intervention group
Group type: EXPERIMENTAL
Intervention: Halita mouthwash (chlorhexidine, cetylpyridinium chloride, zinc lactate)
Number of subjects: 40
Study 12716335 — intervention group
Group type: EXPERIMENTAL
Intervention: Halita mouthwash
Number of subjects: 40
Study 11053331 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia (17.42% O(2))
Number of subjects: 8
Study 11053331 — intervention group
Group type: COMPARATOR
Intervention: Normoxia (20.93% O(2))
Number of subjects: 8
Study 7818061 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine-propofol combination
Number of subjects: 0
Study 7818061 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide-propofol combination
Number of subjects: 0
Study 7818061 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study 3178907 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ)
Number of subjects: 162
Study 3178907 — intervention group
Group type: EXPERIMENTAL
Intervention: D-penicillamine (DP)
Number of subjects: 162
Study 3178907 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study 29863392 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Questionnaire (GQ) + Outcome Questionnaire-45 (OQ-45)
Number of subjects: 430
Study 29863392 — intervention group
Group type: COMPARATOR
Intervention: Outcome Questionnaire-45 (OQ-45)
Number of subjects: 430
Study 28251755 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac-specific troponin I
Number of subjects: 1653
Study 28251755 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelin-1
Number of subjects: 1653
Study 28251755 — intervention group
Group type: EXPERIMENTAL
Intervention: Several biomarkers (individually and in combination)
Number of subjects: 1653
Study 25042595 — intervention group
Group type: EXPERIMENTAL
Intervention: DAV132
Number of subjects: 18
Study 25042595 — intervention group
Group type: COMPARATOR
Intervention: FAC
Number of subjects: 18
Study 25042595 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 18
Study 23593631 — intervention group
Group type: COMPARATOR
Intervention: acid etching + Single Bond (SB) (control)
Number of subjects: 56
Study 23593631 — intervention group
Group type: EXPERIMENTAL
Intervention: acid etching + SB + Nd:YAG laser irradiation (before adhesive curing)
Number of subjects: 56
Study 23593631 — intervention group
Group type: EXPERIMENTAL
Intervention: thermal etching with the Er:YAG laser + SB
Number of subjects: 56
Study 23593631 — intervention group
Group type: EXPERIMENTAL
Intervention: thermal etching with the Er:YAG laser + SB + Nd:YAG laser irradiation (before adhesive curing)
Number of subjects: 56
Study 21193287 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Manual Edema Mobilization (MEM) treatment
Number of subjects: 0
Study 21193287 — intervention group
Group type: COMPARATOR
Intervention: Traditional edema treatment
Number of subjects: 0
Study 19661926 — intervention group
Group type: EXPERIMENTAL
Intervention: CISalt (1% sodium content)
Number of subjects: 248
Study 19661926 — intervention group
Group type: COMPARATOR
Intervention: Normal salt (8% or 1% sodium content)
Number of subjects: 248
Study 17922975 — intervention group
Group type: EXPERIMENTAL
Intervention: irinotecan/cisplatin (IP)
Number of subjects: 535
Study 14709456 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (30 ng.mL(‐1) target effect site concentration)
Number of subjects: 39
Study 14709456 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 11167476 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 90
Study 11167476 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 90
Study 11167476 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 90
Study 9514561 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin administered subcutaneously in the right forehead to evoke a burning painful sensation.
Number of subjects: 7
Study 9514561 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin administration
Number of subjects: 7
Study 7593655 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% sucrose solution (g/100 mL)
Number of subjects: 57
Study 7593655 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 57
Study 2181031 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine (50 micrograms) administered intramuscularly at weeks 0, 4, and 22
Number of subjects: 161
Study 2181031 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered intramuscularly at weeks 0, 4, and 22
Number of subjects: 161
Study 2181031 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine (50 micrograms)
Number of subjects: 161
Study 282028 — intervention group
Group type: EXPERIMENTAL
Intervention: Wardill-Kilner repair (Group I)
Number of subjects: 47
Study 282028 — intervention group
Group type: COMPARATOR
Intervention: von Langenbeck repair (Group II)
Number of subjects: 47
Study 282028 — intervention group
Group type: EXPERIMENTAL
Intervention: von Langenbeck repair with superiorly based pharyngeal flap (Group III)
Number of subjects: 47
Study 31915983 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosuppressive treatment (number of immunosuppressants)
Number of subjects: 382
Study 31915983 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index (BMI)
Number of subjects: 382
Study 31915983 — intervention group
Group type: EXPERIMENTAL
Intervention: Degree of comorbidity
Number of subjects: 382
Study 31915983 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity of inflammatory activity
Number of subjects: 382
Study 31166571 — intervention group
Group type: EXPERIMENTAL
Intervention: Esketamine nasal spray plus oral antidepressant
Number of subjects: 297
Study 31166571 — intervention group
Group type: COMPARATOR
Intervention: Antidepressant plus placebo nasal spray
Number of subjects: 297
Study 27599663 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous tocilizumab 162 mg every week
Number of subjects: 0
Study 27599663 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous tocilizumab 162 mg every 2 weeks
Number of subjects: 0
Study 27599663 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tocilizumab 8 mg/kg every 4 weeks
Number of subjects: 0
Study 27599663 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous tocilizumab every 2 weeks
Number of subjects: 0
Study 27599663 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous tocilizumab every week
Number of subjects: 0
Study 27599663 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26504777 — intervention group
Group type: EXPERIMENTAL
Intervention: ELISA-IgM
Number of subjects: 1222
Study 26504777 — intervention group
Group type: EXPERIMENTAL
Intervention: Hoffman, Pons, and Janer (HH)
Number of subjects: 1222
Study 26504777 — intervention group
Group type: EXPERIMENTAL
Intervention: Kato-Katz (KK)
Number of subjects: 1222
Study 26504777 — intervention group
Group type: EXPERIMENTAL
Intervention: qPCR-serum
Number of subjects: 1222
Study 26504777 — intervention group
Group type: EXPERIMENTAL
Intervention: ELISA-IgG
Number of subjects: 1222
Study 26504777 — intervention group
Group type: EXPERIMENTAL
Intervention: IFT-IgM
Number of subjects: 1222
Study 26504777 — intervention group
Group type: EXPERIMENTAL
Intervention: All techniques except qPCR-serum
Number of subjects: 1222
Study 23866917 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential stage-matched intervention targeting procurement and consumption of fruits, vegetables, salt, sugar, and oil; delivered over 1 year with strategies at 0, 6, and 12 months, including counselling sessions, telephonic reminders, and home visits.
Number of subjects: 0
Study 23866917 — intervention group
Group type: COMPARATOR
Intervention: Control group received information on recommended levels of intake of the five dietary components and general dietary information leaflets.
Number of subjects: 0
Study 21311065 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid Angioplasty and Stenting (CAS)
Number of subjects: 507
Study 21311065 — intervention group
Group type: COMPARATOR
Intervention: Carotid Endarterectomy (CEA)
Number of subjects: 507
Study 19827881 — intervention group
Group type: EXPERIMENTAL
Intervention: Riboflavin-fortified salt
Number of subjects: 22893
Study 19827881 — intervention group
Group type: COMPARATOR
Intervention: Control group (no riboflavin-fortified salt)
Number of subjects: 22893
Study 16205845 — intervention group
Group type: EXPERIMENTAL
Intervention: Lying position
Number of subjects: 20
Study 16205845 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing position
Number of subjects: 20
Study 16205845 — intervention group
Group type: COMPARATOR
Intervention: Various positions (crook lying, supine, sitting, standing)
Number of subjects: 20
Study 14767169 — intervention group
Group type: EXPERIMENTAL
Intervention: Urea-containing gum
Number of subjects: 11
Study 14767169 — intervention group
Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 11
Study 14767169 — intervention group
Group type: EXPERIMENTAL
Intervention: Urea rinsing
Number of subjects: 11
Study 11332061 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine 0.5% with saline (3 mg.kg‐1)
Number of subjects: 45
Study 11332061 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 0.5% with clonidine (150 micrograms) (3 mg.kg‐1)
Number of subjects: 45
Study 9202914 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mL of anaesthetic solution (0.5% bupivacaine with adrenaline 1:200,000 and 2% lignocaine)
Number of subjects: 90
Study 9202914 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mL of anaesthetic solution (0.5% bupivacaine with adrenaline 1:200,000 and 2% lignocaine)
Number of subjects: 90
Study 9202914 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mL of anaesthetic solution (0.5% bupivacaine with adrenaline 1:200,000 and 2% lignocaine)
Number of subjects: 90
Study 7881027 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (1 mg/day)
Number of subjects: 441
Study 7881027 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (1000 mg/day)
Number of subjects: 441
Study 7881027 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (300 mg/day)
Number of subjects: 441
Study 7881027 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine (80 mg/day)
Number of subjects: 441
Study 7881027 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine (50 mg/day)
Number of subjects: 441
Study 7881027 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate (1000 mg/day)
Number of subjects: 441